LivaNova Enters Research Collaboration With Verily To Gain New Insights Into Treatment For Difficult-To-Treat Depression

LivaNova PLC, a medical technology and innovation company, announced a research collaboration with Verily, an Alphabet company, to capture measures of depression within its RECOVER clinical study, which is evaluating the effectiveness of Vagus Nerve Stimulation Therapy® (VNS Therapy) for Difficult-to-Treat Depression (DTD). Through this initial research collaboration, LivaNova and Verily aim to gather quantitative data on behavior using technology and analytics developed by Verily to further understand depressive episodes and an individual's response to treatment. RECOVER clinical sites will have the ability to offer participants the Verily Study Watch, a wearable device designed to capture physiological . . .